{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:29:13Z","timestamp":1792099753492,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1038\/sj.bjc.6605211","type":"journal-article","created":{"date-parts":[[2009,8,11]],"date-time":"2009-08-11T22:52:26Z","timestamp":1250031146000},"page":"621-627","source":"Crossref","is-referenced-by-count":233,"title":["Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study \u2013 The UK ABC-01 Study"],"prefix":"10.1038","volume":"101","author":[{"given":"J W","family":"Valle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Wasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Swindell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Baka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Maraveyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Corrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Gollins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Lofts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Anthoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Iveson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Highley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Bridgewater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,8,11]]},"reference":[{"key":"BF6605211_CR1","unstructured":"Agelaki S, Papakostas P, Stathopoulos G, Aravantinos G, Kalbakis K, Sarra E, Souglakos J, Kakolyris S, Kouroussis S, Androulakis N, Vardakis N, Georgoulias V (1999) Phase II study of docetaxel with G-CSF support as first-line treatment for unresectable or advanced biliary tract carcinoma: a multicentre phase II trial. Proc Am Soc Clin Oncol 18: 276a (abstract 1058)"},{"key":"BF6605211_CR2","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/0959-8049(95)00419-X","volume":"31a","author":"BJ Braakhuis","year":"1995","unstructured":"Braakhuis BJ, Ruiz van Haperen VW, Welters MJ, Peters GJ (1995) Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 31a: 2335\u20132340","journal-title":"Eur J Cancer"},{"key":"BF6605211_CR3","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris III","year":"1997","unstructured":"Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial [see comments]. J Clin Oncol 15: 2403\u20132413","journal-title":"J Clin Oncol"},{"key":"BF6605211_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/BF00873232","volume":"12","author":"ES Casper","year":"1994","unstructured":"Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG (1994) Phase II trial of gemcitabine (2,2\u2032-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12: 29\u201334","journal-title":"Invest New Drugs"},{"key":"BF6605211_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/00000421-200008000-00023","volume":"23","author":"CW Choi","year":"2000","unstructured":"Choi CW, Choi IK, Seo JH, Kim BS, Kim JS, Kim CD, Um SH, Kim YH (2000) Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 23: 425\u2013428","journal-title":"Am J Clin Oncol"},{"key":"BF6605211_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/01.mpa.0000188306.67420.0f","volume":"32","author":"AJ Clayton","year":"2006","unstructured":"Clayton AJ, Mansoor AW, Jones ET, Hawkins RE, Saunders MP, Swindell R, Valle JW (2006) A phase II study of weekly cisplatin and gemcitabine in patients with advanced pancreatic cancer: is this a strategy still worth pursuing? Pancreas 32: 51\u201357","journal-title":"Pancreas"},{"key":"BF6605211_CR7","unstructured":"Coleman MP, Babb P, Damiecki P, Grosclaude P, Honjo S, Jones J, Knerer G, Pitard A, Quinn M, Flogett A, Stavola B (1999) Cancer Survival Trends in England and Wales 1971\u20131995: deprivation and NHS region. The Stationery Office: London. pp 237\u2013234"},{"key":"BF6605211_CR8","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/0959-8049(96)00155-4","volume":"32a","author":"P Comella","year":"1996","unstructured":"Comella P, Palmieri G, Lorusso V, Catalano G, Nicollela D, Ianniello GP, Casaretti R, Montella M, Frasci G, Perna M, Comella G (1996) Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies. Eur J Cancer 32a: 1719\u20131726","journal-title":"Eur J Cancer"},{"key":"BF6605211_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1155\/2005\/565479","volume":"19","author":"BH Dingle","year":"2005","unstructured":"Dingle BH, Rumble RB, Brouwers MC (2005) The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: a systematic review. Can J Gastroenterol 19: 711\u2013716","journal-title":"Can J Gastroenterol"},{"key":"BF6605211_CR10","first-page":"296a","volume":"19","author":"T Dragovich","year":"2000","unstructured":"Dragovich T, Ramanthan RK, Remick S, Dyky MA, Wade-Oliver KT, Jacobs S, Mani S, KIndler HL (2000) Phase II trial of a weekly 150-min gemcitabine infusion in patients with biliary tree carcinomas. Proc Am Soc Clin Oncol 19: 296a abstract 1159","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6605211_CR11","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1023\/A:1008241008379","volume":"9","author":"M Ducreux","year":"1998","unstructured":"Ducreux M, Rougier P, Fandi A, Clavero-Fabri MC, Villing AL, Fassone F, Fandi L, Zarba J, Armand JP (1998) Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 9: 653\u2013656","journal-title":"Ann Oncol"},{"key":"BF6605211_CR12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.ejca.2004.10.026","volume":"41","author":"M Ducreux","year":"2005","unstructured":"Ducreux M, Van Cutsem E, Van Laethem JL, Gress TM, Jeziorski K, Rougier P, Wagener T, Anak O, Baron B, Nordlinger B (2005) A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer 41: 398\u2013403","journal-title":"Eur J Cancer"},{"key":"BF6605211_CR13","first-page":"283a","volume":"19","author":"F Eckel","year":"2000","unstructured":"Eckel F, Lersch C, Assmann G, Schulte-Frohlinde E (2000) Toxicity of a 24-h infusion of gemcitabine in biliary tract and pancreatic cancer. Proc Am Soc Clin Oncol 19: 283a (abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6605211_CR14","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","volume":"96","author":"F Eckel","year":"2007","unstructured":"Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96: 896\u2013902","journal-title":"Br J Cancer"},{"key":"BF6605211_CR15","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1007\/s00259-003-1438-0","volume":"31","author":"DL Francis","year":"2004","unstructured":"Francis DL, Visvikis D, Costa DC, Croasdale I, Arulampalam TH, Luthra SK, Taylor I, Ell PJ (2004) Assessment of recurrent colorectal cancer following 5-fluorouracil chemotherapy using both 18FDG and 18FLT PET. Eur J Nucl Med Mol Imaging 31: 928","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"BF6605211_CR16","first-page":"268a","volume":"19","author":"J Gallardo","year":"2000","unstructured":"Gallardo J, Rubio B, Fodor M, Orlandi L, Yanez M, Gamargo C, Ahumada M, Oliva J (2000) Gemcitabine (gem): an active drug in advanced gallbladder cancer (AGC). Proc Am Soc Clin Oncol 19: 268a abstract 1042","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6605211_CR17","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1002\/(SICI)1097-0142(19960915)78:6<1300::AID-CNCR19>3.0.CO;2-4","volume":"78","author":"V Gebbia","year":"1996","unstructured":"Gebbia V, Majello E, Testa A, Pezzella G, Giuseppe S, Giotta F, Riccardi F, Fortunato S, Colucci G, Gebbia N (1996) Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). Cancer 78: 1300\u20131307","journal-title":"Cancer"},{"key":"BF6605211_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","volume":"7","author":"B Glimelius","year":"1996","unstructured":"Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Linne T, Svensson C (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7: 593\u2013600","journal-title":"Ann Oncol"},{"key":"BF6605211_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/00000421-199406000-00008","volume":"17","author":"M Kajanti","year":"1994","unstructured":"Kajanti M, Pyrhonen S (1994) Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study. Am J Clin Oncol 17: 223\u2013226","journal-title":"Am J Clin Oncol"},{"key":"BF6605211_CR20","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1200\/JCO.1997.15.3.947","volume":"15","author":"J Klempnauer","year":"1997","unstructured":"Klempnauer J, Ridder GJ, von Wasielewski R, Werner M, Weimann A, Pichlmayr R (1997) Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J Clin Oncol 15: 947\u2013954","journal-title":"J Clin Oncol"},{"key":"BF6605211_CR21","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/annonc\/mdh096","volume":"15","author":"GV Kornek","year":"2004","unstructured":"Kornek GV, Schuell B, Laengle F, Gruenberger T, Penz M, Karall K, Depisch D, Lang F, Scheithauer W (2004) Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol 15: 478\u2013483","journal-title":"Ann Oncol"},{"key":"BF6605211_CR22","first-page":"264a","volume":"19","author":"RD Lozano","year":"2000","unstructured":"Lozano RD, Patt YZ, Hassan MM, Frome A, Vauthey JN, Ellis LM, Schnirer I, Brown TD, Abbruzzese JL, Wolff RA, Charnsangavej C (2000) Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer). Proc Am Soc Clin Oncol 19: 264a (abstract 1025)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6605211_CR23","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa032295","volume":"350","author":"JP Neoptolemos","year":"2004","unstructured":"Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Buchler MW (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350: 1200\u20131210","journal-title":"N Engl J Med"},{"key":"BF6605211_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jama.297.3.267","volume":"297","author":"H Oettle","year":"2007","unstructured":"Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297: 267\u2013277","journal-title":"JAMA"},{"key":"BF6605211_CR25","first-page":"297a","volume":"18","author":"YZ Patt","year":"1999","unstructured":"Patt YZ, Hassan MM, Lozano RD, Hoque AM, Raijman I, Waugh KA (1999) Phase II trial of cisplatin (P), Intron A (I), Adriamycin (A), and 5-fluorouracil (F)(PIAF) for biliary tree cancer (BTC). Proc Am Soc Clin Oncol 18: 297a (abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6605211_CR26","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1200\/JCO.1996.14.8.2311","volume":"14","author":"YZ Patt","year":"1996","unstructured":"Patt YZ, Jones Jr DV, Hoque A, Lozano R, Markowitz A, Raijman I, Lynch P, Charnsangavej C (1996) Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 14: 2311\u20132315","journal-title":"J Clin Oncol"},{"key":"BF6605211_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000011961","volume":"56","author":"M Raderer","year":"1999","unstructured":"Raderer M, Hejna MH, Valencak JB, Kornek GV, Weinlander GS, Bareck E, Lenauer J, Brodowicz T, Lang F, Scheithauer W (1999) Two consecutive phase II studies of 5-fluorouracil\/leucovorin\/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 56: 177\u2013180","journal-title":"Oncology"},{"key":"BF6605211_CR28","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1038\/sj.bjc.6602576","volume":"92","author":"S Rao","year":"2005","unstructured":"Rao S, Cunningham D, Hawkins RE, Hill ME, Smith D, Daniel F, Ross PJ, Oates J, Norman AR (2005) Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 92: 1650\u20131654","journal-title":"Br J Cancer"},{"key":"BF6605211_CR29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/oxfordjournals.annonc.a010600","volume":"7","author":"ML Rothenberg","year":"1996","unstructured":"Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris III HA, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, Von Hoff DD (1996) A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer [see comments]. Ann Oncol 7: 347\u2013353","journal-title":"Ann Oncol"},{"key":"BF6605211_CR30","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1002\/1097-0142(19841015)54:8<1513::AID-CNCR2820540806>3.0.CO;2-9","volume":"54","author":"GW Smith","year":"1984","unstructured":"Smith GW, Bukowski RM, Hewlett JS, Groppe CW (1984) Hepatic artery infusion of 5-fluorouracil and mitomycin C in cholangiocarcinoma and gallbladder carcinoma. Cancer 54: 1513\u20131516","journal-title":"Cancer"},{"key":"BF6605211_CR31","first-page":"306a","volume":"16","author":"AM Storniolo","year":"1997","unstructured":"Storniolo AM, Enas NH, Brown CA, Schilsky R (1997) Treatment investigational new drug program for Gemzar (gemcitabine HCl) in patients with pancreas cancer (PaCa). Proc Am Soc Clin Oncol 16: 306a (abstract 1088)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6605211_CR32","first-page":"825","volume":"12","author":"C Theodossiou","year":"1998","unstructured":"Theodossiou C, Cook JA, Fisher J, Teague D, Liebmann JE, Russo A, Mitchell JB (1998) Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines. Int J Oncol 12: 825\u2013832","journal-title":"Int J Oncol"},{"key":"BF6605211_CR33","first-page":"305a","volume":"18","author":"A Weissmann","year":"1999","unstructured":"Weissmann A, Ludwig H (1999) Intraarterial gemcitabine for treatment of inoperable pancreatic and cholangiocarcinoma. Proc Am Soc Clin Oncol 18: 305a (abstract 1170)","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6605211.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605211","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605211.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:41:07Z","timestamp":1684413667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6605211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["BF6605211"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6605211","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}